TY - JOUR
T1 - Predictive value of 99mTc-MAA SPECT for 90Y-labeled resin microsphere distribution in radioembolization of primary and secondary hepatic tumors
AU - Ilhan, Harun
AU - Goritschan, Anna
AU - Paprottka, Philipp
AU - Jakobs, Tobias F.
AU - Fendler, Wolfgang P.
AU - Todica, Andrei
AU - Bartenstein, Peter
AU - Hacker, Marcus
AU - Haug, Alexander R.
N1 - Publisher Copyright:
Copyright © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PY - 2015/11/1
Y1 - 2015/11/1
N2 - This study analyzed the predictive value of 99mTc-labeled macroaggre-gated albumin (99mTc-MAA) SPECT for 90Y-labeled resin microsphere therapy (radioembolization) by comparing uptake on pretherapeutic 99mTc-MAA SPECT with uptake on posttherapeutic 90Y-bremsstrahlung SPECT. Methods: We included 502 patients (55% male; mean age ± SD, 62 ± 11 y) who underwent radioembolization between 2005 and 2013 because of primary or secondary liver malignancies (colorectal cancer [n = 195, 38.8%], neuroendocrine tumors [n = 77, 15.3%], breast cancer [n = 68, 13.5%], hepatocellular carcinoma [n = 59, 11.8%], cholangiocellular carcinoma [n = 40, 8.0%], or urologic tumors [n = 14, 2.8%]). Manually drawn regions of interest around tumors and adjacent healthy liver tissue for up to 3 lesions per patient on 99mTc-MAA and 90Y-bremsstrahlung scans were used to quantify mean counts per pixel and evaluate the mean tumor-to-background ratio (TBR). Data were given as mean ± SD. Additionally, uptake in lesions on 99mTc-MAA and 90Y-bremsstrahlung scans was graded visually as homogeneously higher than (grade 1), heterogeneously higher than (grade 2), equal to (grade 3), or lower than (grade 4) uptake in normal liver tissue. The Mann-Whitney U test and Spearman correlation were used to evaluate statistically significant differences between 99mTc-MAA and 90Y-bremsstrahlung SPECT. Results: In total, 1,008 lesions were analyzed. Of the 23% (230/1,008) of lesions that had grade 1 uptake on 99mTc-MAA SPECT, 81% (186/230) remained grade 1 after radioembolization whereas 16% (37/230) were grade 2. Of the lesions with grade 2 uptake on 99mTc-MAA SPECT, 16% had grade 1 uptake and 82% grade 2 uptake after radioembolization. Of the lesions with grade 3 uptake, however, 27% had grade 1 uptake and 47% grade 2 uptake after radioembolization. Even among the lesions with grade 4 uptake on 99mTc-MAA SPECT, 21% had grade 1 uptake and 46% grade 2 uptake after radioembolization. The mean TBR on 99mTc-MAA and 90Y-bremsstrahlung SPECT showed a significant, though low, correlation in the total population (r = 0.26; P < 0.001) and in hepatocellular carcinoma (r = 0.4; P < 0.001), cholangiocellular carcinoma (r = 0.3; P < 0.05), breast cancer (r = 0.3; P < 0.001), colorectal cancer (r = 0.2; P < 0.001), and neuroendocrine tumors (r = 0.2; P < 0.01). Conclusion: Although significant for most lesions, the correlation between 99mTc-MAA and 90Y-microsphere mean TBR was low. Classifying uptake into 4 grades revealed that lesions with high uptake on 99mTc-MAA SPECT maintain high uptake within radioembolization. More than 60% of lesions with a pretherapeutically lower uptake than in healthy liver tissue, however, showed high uptake within radioembolization. Patients with low tumor uptake on pretherapeutic 99mTc-MAA imaging should not be excluded from radioembolization.
AB - This study analyzed the predictive value of 99mTc-labeled macroaggre-gated albumin (99mTc-MAA) SPECT for 90Y-labeled resin microsphere therapy (radioembolization) by comparing uptake on pretherapeutic 99mTc-MAA SPECT with uptake on posttherapeutic 90Y-bremsstrahlung SPECT. Methods: We included 502 patients (55% male; mean age ± SD, 62 ± 11 y) who underwent radioembolization between 2005 and 2013 because of primary or secondary liver malignancies (colorectal cancer [n = 195, 38.8%], neuroendocrine tumors [n = 77, 15.3%], breast cancer [n = 68, 13.5%], hepatocellular carcinoma [n = 59, 11.8%], cholangiocellular carcinoma [n = 40, 8.0%], or urologic tumors [n = 14, 2.8%]). Manually drawn regions of interest around tumors and adjacent healthy liver tissue for up to 3 lesions per patient on 99mTc-MAA and 90Y-bremsstrahlung scans were used to quantify mean counts per pixel and evaluate the mean tumor-to-background ratio (TBR). Data were given as mean ± SD. Additionally, uptake in lesions on 99mTc-MAA and 90Y-bremsstrahlung scans was graded visually as homogeneously higher than (grade 1), heterogeneously higher than (grade 2), equal to (grade 3), or lower than (grade 4) uptake in normal liver tissue. The Mann-Whitney U test and Spearman correlation were used to evaluate statistically significant differences between 99mTc-MAA and 90Y-bremsstrahlung SPECT. Results: In total, 1,008 lesions were analyzed. Of the 23% (230/1,008) of lesions that had grade 1 uptake on 99mTc-MAA SPECT, 81% (186/230) remained grade 1 after radioembolization whereas 16% (37/230) were grade 2. Of the lesions with grade 2 uptake on 99mTc-MAA SPECT, 16% had grade 1 uptake and 82% grade 2 uptake after radioembolization. Of the lesions with grade 3 uptake, however, 27% had grade 1 uptake and 47% grade 2 uptake after radioembolization. Even among the lesions with grade 4 uptake on 99mTc-MAA SPECT, 21% had grade 1 uptake and 46% grade 2 uptake after radioembolization. The mean TBR on 99mTc-MAA and 90Y-bremsstrahlung SPECT showed a significant, though low, correlation in the total population (r = 0.26; P < 0.001) and in hepatocellular carcinoma (r = 0.4; P < 0.001), cholangiocellular carcinoma (r = 0.3; P < 0.05), breast cancer (r = 0.3; P < 0.001), colorectal cancer (r = 0.2; P < 0.001), and neuroendocrine tumors (r = 0.2; P < 0.01). Conclusion: Although significant for most lesions, the correlation between 99mTc-MAA and 90Y-microsphere mean TBR was low. Classifying uptake into 4 grades revealed that lesions with high uptake on 99mTc-MAA SPECT maintain high uptake within radioembolization. More than 60% of lesions with a pretherapeutically lower uptake than in healthy liver tissue, however, showed high uptake within radioembolization. Patients with low tumor uptake on pretherapeutic 99mTc-MAA imaging should not be excluded from radioembolization.
KW - Liver tumor
KW - SIRT
KW - SPECT/CT
KW - Tc macroaggregated albumin
KW - Y radioembolization
UR - http://www.scopus.com/inward/record.url?scp=84946566607&partnerID=8YFLogxK
U2 - 10.2967/jnumed.115.162685
DO - 10.2967/jnumed.115.162685
M3 - Article
C2 - 26315830
AN - SCOPUS:84946566607
SN - 0161-5505
VL - 56
SP - 1654
EP - 1660
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 11
ER -